TW202135790A - Ghb給藥 - Google Patents

Ghb給藥 Download PDF

Info

Publication number
TW202135790A
TW202135790A TW109145587A TW109145587A TW202135790A TW 202135790 A TW202135790 A TW 202135790A TW 109145587 A TW109145587 A TW 109145587A TW 109145587 A TW109145587 A TW 109145587A TW 202135790 A TW202135790 A TW 202135790A
Authority
TW
Taiwan
Prior art keywords
mixed
oxybutyrate
oxybate
weight
administered
Prior art date
Application number
TW109145587A
Other languages
English (en)
Chinese (zh)
Inventor
法蘭克 斯科比蘭達
Original Assignee
愛爾蘭商爵士製藥愛爾蘭有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商爵士製藥愛爾蘭有限責任公司 filed Critical 愛爾蘭商爵士製藥愛爾蘭有限責任公司
Publication of TW202135790A publication Critical patent/TW202135790A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
TW109145587A 2019-12-24 2020-12-22 Ghb給藥 TW202135790A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US62/953,288 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US62/993,372 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US63/000,547 2020-03-27
US202063052676P 2020-07-16 2020-07-16
US63/052,676 2020-07-16

Publications (1)

Publication Number Publication Date
TW202135790A true TW202135790A (zh) 2021-10-01

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109145587A TW202135790A (zh) 2019-12-24 2020-12-22 Ghb給藥

Country Status (14)

Country Link
US (3) US20210186907A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081204A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023508975A (cg-RX-API-DMAC7.html)
KR (1) KR20220119429A (cg-RX-API-DMAC7.html)
CN (1) CN115209885A (cg-RX-API-DMAC7.html)
AU (1) AU2020414694A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012594A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162974A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001743A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010330A2 (cg-RX-API-DMAC7.html)
IL (1) IL294176A (cg-RX-API-DMAC7.html)
MX (1) MX2022007968A (cg-RX-API-DMAC7.html)
TW (1) TW202135790A (cg-RX-API-DMAC7.html)
WO (1) WO2021133778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
CN115209885A (zh) 2022-10-18
WO2021133778A1 (en) 2021-07-01
BR112022012594A2 (pt) 2022-09-06
MX2022007968A (es) 2022-09-02
US20240285560A1 (en) 2024-08-29
CA3162974A1 (en) 2021-07-01
AU2020414694A1 (en) 2022-08-18
IL294176A (en) 2022-08-01
US20210186907A1 (en) 2021-06-24
US20210361601A1 (en) 2021-11-25
CO2022010330A2 (es) 2022-10-21
EP4081204A1 (en) 2022-11-02
JP2023508975A (ja) 2023-03-06
CL2022001743A1 (es) 2023-02-10
KR20220119429A (ko) 2022-08-29

Similar Documents

Publication Publication Date Title
JP2023508975A (ja) ガンマ-ヒドロキシ酪酸塩(ghb)投薬
TWI812557B (zh) 伽瑪(γ)-羥基丁酸鹽組合物及其用於治療病症之用途
Bailey Metformin: Therapeutic profile in the treatment of type 2 diabetes
US20250073192A1 (en) Methods of treating idiopathic hypersomnia
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
EP1765075A1 (en) Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
US12582622B2 (en) Sodium oxybate to treat idiopathic hypersomnia
WO2005123097A1 (en) Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
MX2011013989A (es) Combinacion farmaceutica.
WO2025170080A1 (ja) 二日酔いの予防または改善剤
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
CN112716945A (zh) 药物组合物及其应用